Nordea Investment Management AB Grows Stock Holdings in Zoetis Inc. $ZTS

Nordea Investment Management AB raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 2,356,166 shares of the company’s stock after buying an additional 214,889 shares during the period. Nordea Investment Management AB’s holdings in Zoetis were worth $368,245,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis during the first quarter valued at about $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis during the first quarter valued at about $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the first quarter valued at about $29,000. Cornerstone Planning Group LLC lifted its position in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $143.14 on Friday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company’s 50 day moving average is $148.79 and its 200 day moving average is $153.88. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $63.44 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 2.28 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ZTS shares. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.